JPRN-UMIN000016136尚未招募未知
A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-dily fluticasone propionate/salmeterol in elderly patients with asthma - The efficacy of fluticasone furoate/vilanterole in elderly asthmatics
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 60years-old 至 95years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Unsle elderly asthma
研究者
相似试验
进行中（未招募）
不适用
A 24-week study to evaluate the effect of fluticasone furoate/ vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol in subjects with Chronic Obstructive Pulmonary Disease (COPD). - N/AChronic Obstructive Pulmonary Disease (COPD).MedDRA version: 16.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2010-023091-10-DEGlaxoSmithKline Research & Development Ltd408
进行中（未招募）
1 期
A 24-week study to evaluate the effect of fluticasone furoate/ vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol in subjects with Chronic Obstructive Pulmonary Disease (COPD). - N/AChronic Obstructive Pulmonary Disease (COPD).MedDRA version: 12.1 Level: LLT Classification code 10010952 Term: COPDEUCTR2010-023091-10-NOGlaxoSmithKline Research & Development Ltd3,011
进行中（未招募）
不适用
12 week Chronic Obstructive Pulmonary Disease (COPD)studysubjects with Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-024435-16-DEGlaxoSmithKline Research & Development Ltd248
进行中（未招募）
不适用
A 12-week study to evaluate the effect of the drug fluticasone furoate/vilanterol at the dose of 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) on arterial stiffness compared with the drug Tiotropium bromide at the dose of 18 mcg delivered once daily via a HandiHaler in subjects with Chronic Obstructive Pulmonary Disease (COPD)EUCTR2010-024435-16-ITGlaxoSmithKline Research & Development Ltd248
尚未招募
4 期
Glargine once versus twice dailyCTRI/2023/10/059275surbhi bharti